Validated stability-indicating chromatographic method for the assay of erlotinib active pharmaceutical ingredient

Analytical Letters

Volumn 42, Issue 12, 2009, Pages 1855-1867

  Pujeri, S S ^a   Khader, A M A ^a   Seetharamappa, J ^b  

^a MANGALORE UNIVERSITY   (India)

^b KARNATAK UNIVERSITY   (India)

Author keywords

Erlotinib; Forced degradation; Reverse phase; Stability indicating; Validation

Indexed keywords

EID: 70449364826     PISSN: 00032719     EISSN: 1532236X     Source Type: Journal    
DOI: 10.1080/00032710903061170     Document Type: Article

References (8)

1. Cohen, M. H., J. R. Johnson, Y. F. Chen, R. Sridhar, and R. Pazdur. 2005. FDA drug approval summary: Erlotinib (Tarceva1) tablets. Oncologist 10: 461-466.
2. Dowell, J., J. D. Minna, and P. Kirkpatrick. 2005. Erlotinib: Small-molecule targeted therapy in the treatment of non-small-cell lung cancer. Nat. Rev. 4: 13-14.
3. ICH. 1999. Topic Q1A (R2): Stability testing of new drug substances and products (CPMP=ICH=2736=99). Available at http://www.ich.org/LOB/media/MEDIA430.pdf
4. ICH. 1996. Topic Q2 (R1): Validation of analytical procedures: Text and methodology (CPMP=ICH=381=95). Available at http://www.ich.org/LOB/media/MEDIA417[1].pdf
5. Lepper, E. R., S. M. Swain, A. R. Tan, W. D. Figg, and A. Sparreboom. 2003. Liquid-chromatographic determination of erlotinib (OSI-774), an epidermal growth factor receptor tyrosine kinase inhibitor. J. Chromatogr. B 796(1): 181-188.
6. Masters, A. R., C. J. Sweeney, and D. R. Jones. 2007. The quantification of erlotinib (OSI-774) and OSI-420 in human plasma by liquid chromatographytandem mass spectrometry. J. Chromatogr. B 848(2): 379-383.
7. Zhang, W., L. L. Siu, M. J. Moore, and E. X. Chen. 2005. Simultaneous determination of OSI-774 and its major metabolite OSI-420 in human plasma by using HPLC with UV detection. J. Chromatogr. B 814(1): 143-147.
8. Zhao, M., P. He, M. A. Rudek, M. Hidalgo, and S. D. Baker. 2003. Specific method for determination of OSI-774 and its metabolite OSI-420 in human plasma by using liquid chromatography-tandem mass spectrometry. J. Chromatogr. B 793(2): 413-420.